Table 2

De novo inhibitors occurring in previously treated patients with hemophilia A who switched from plasma-derived to recombinant FVIII during prospective licensure studies

Recombinant productNo. of patientsNo. of de novo inhibitors
Recombinate (full-length)43690
Kogenate (full-length)44861
Kogenate-FS (full-length)45730
Refacto (B-domainless)461131
Advate (full-length)471081
Refacto (B-domainless)482043